查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046006

泌尿生殖系統藥物市場－全球產業規模、佔有率、趨勢、機會與預測：按適應症、產品、地區和競爭格局分類，2021-2031年

Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Product, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球泌尿生殖系統藥物市場預計將從 2025 年的 287.9 億美元成長到 2031 年的 335.6 億美元，複合年成長率為 2.59%。

此領域涵蓋治療泌尿系統和生殖系統疾病的藥物，例如良性前列腺增生、尿失禁和各種泌尿生殖系統癌症。市場成長的主要促進因素是全球人口老化（老年人更容易患慢性泌尿系統疾病）以及癌症發生率的上升，這兩種疾病都需要持續的藥物治療。

市場概覽
預測期 2027-2031
市場規模：2025年 287.9億美元
市場規模：2031年 335.6億美元
複合年成長率：2026-2031年 2.59%
成長最快的細分市場 荷爾蒙療法
最大的市場 北美洲

市場擴張的主要限制因素在於關鍵泌尿生殖系統藥物專利到期。專利保護期的喪失使得價格更低廉的學名藥得以上市，導致現有製藥公司利潤下降，價格競爭加劇。因此，企業在推出新化合物時面臨雙重挑戰：嚴格的監管核准流程和高昂的研發成本。這些因素可能會阻礙整個行業的成長。

市場促進因素

市場的主要促進因素是泌尿生殖系統惡性腫瘤（尤其是膀胱癌和前列腺癌）發生率的不斷上升。全球人口老化加劇了這些疾病的激增，因此需要多種藥物療法，從局部膀胱內治療到全身性化療。全球統計數據也印證了這項需求。根據世界衛生組織（WHO）估計，2022年全球新增膀胱癌病例約614,298例。此外，根據美國癌症協會預測，到2024年，攝護腺癌將佔全球整體所有新診斷癌症病例的7.3%。日益加重的疾病負擔確保了在疾病進展的各個階段對有效泌尿器官系統藥物的持續需求。

生物製藥和標靶藥物遞送系統的顯著進步正在改變競爭格局，並推動收入成長。製藥公司正日益關注抗體藥物複合體（ADC）和免疫查核點抑制劑，以突破傳統化療的限制，在難治性病例中提供更佳療效。這種轉變在新型尿路上皮癌治療方法的快速市場滲透中得到了清晰體現。Astellas來製藥公司報告稱，其標靶治療藥物Padsev在2024會計年度的全球銷售額達到1,641億日元，年增92%。這些創新不僅改善了患者的治療效果，也帶來了更高的定價，最終提升了泌尿生殖系統藥物市場的整體價值。

市場挑戰

重磅藥物專利到期對全球泌尿生殖系統藥物市場的成長構成重大阻礙。當前列腺癌和良性前列腺增生等疾病的成熟治療方法的市場主導地位終結時，價格更低廉的學名藥和生物類似藥會立即湧入市場，形成競爭。這種現象導致原廠藥生產商的市佔率迅速下降，因為高價品牌藥被低價學名藥所取代，最終導致該產業整體市場規模大幅萎縮。因此，該產業的重要收入來源也隨之減少。

企業獲利下滑造成了難以預測的局面，限制了製藥公司可用於高風險研發的資金，而這些研發對於創新泌尿器官系統藥物通過法規核准至關重要。品牌藥收入向醫療成本降低的資金轉移幅度龐大。例如，根據美國可及藥品協會（Association for Accessible Medicines）的報告，到2024年，生物相似藥的使用將使醫療成本降低202億美元。這一巨額數字清楚地表明了失去壟斷地位所帶來的嚴重經濟影響，並證實了單位收入的下降正在阻礙市場的永續經濟成長。

市場趨勢

放射性配體療法的引入是轉移性前列腺癌精準腫瘤學領域的重大進展，它能夠將放射線直接靶向前列腺特異性膜抗原（PSMA）陽性細胞。對於那些儘管接受過雄激素受體路徑抑制劑和紫杉烷類化療但病情仍進展的患者而言，這種方法提供了一種強效的新選擇，超越了傳統的全身性治療。這類藥物的商業性成功體現在這些新型放射性藥物的快速市場接受度。諾華公司報告稱，Pluvicto在2024年第三季的銷售額達到3.86億美元，年增50%。這一成長表明，放射性配體療法正日益成為進行性前列腺癌臨床治療的標準療法。

PARP抑制劑在去勢抗性前列腺癌治療的應用日益廣泛，其對攜帶同源重組修復基因突變的腫瘤具有合成致死性，這正在重塑治療指南。這一趨勢標誌著治療策略正向基於生物標記的治療方法轉變，即根據BRCA1和BRCA2突變等特定基因特徵篩選患者。製藥公司正抓住這一趨勢，尋求核准PARP抑制劑與抗雄性激素聯合使用，以延緩早期轉移性患者的疾病進展。Astra Zeneca的利帕扎（Lymparza）在2024年第三季的銷售額成長了13%，這反映了該公司持續強勁的市場地位以及PARP抑制劑在泌尿泌尿系統治療領域日益重要的作用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：泌尿生殖系統治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 適應症（前列腺癌、卵巢癌、膀胱癌、子宮頸癌、腎癌、勃起功能障礙、尿道感染、尿失禁和膀胱過動症症、性行為感染感染、間質性膀胱炎、血尿、良性前列腺增生）
    • 產品類別（荷爾蒙療法、婦科、泌尿系統、感染疾病物、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美泌尿生殖系統治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲泌尿生殖系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區泌尿生殖系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲泌尿生殖系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲泌尿生殖系統藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球泌尿生殖系統藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott laboratories Ltd.
  • Bristol-Myers Squibb Co.
  • Novartis AG
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • AstraZeneca Plc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18967

The global genitourinary drugs market is anticipated to expand from USD 28.79 billion in 2025 to USD 33.56 billion by 2031, demonstrating a compound annual growth rate (CAGR) of 2.59%. This sector encompasses pharmaceutical products tailored for conditions affecting the urinary tract and reproductive system, such as benign prostatic hyperplasia, urinary incontinence, and various genitourinary cancers. The market's growth is primarily fueled by an aging worldwide population that is more prone to chronic urological ailments and a growing prevalence of cancer, both of which require continuous pharmacological treatment.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 28.79 Billion
Market Size 2031USD 33.56 Billion
CAGR 2026-20312.59%
Fastest Growing SegmentHormonal Therapy
Largest MarketNorth America

A significant impediment to market expansion stems from the patent expirations of leading genitourinary drugs. This loss of exclusivity paves the way for the introduction of more affordable generic alternatives, subsequently eroding revenue for incumbent pharmaceutical companies and heightening competitive pricing pressures. As a result, firms face the dual challenge of stringent regulatory approval processes and substantial development expenses when introducing new compounds, factors that can hinder the industry's broader growth trajectory.

Market Driver

A major driver for market demand is the increasing incidence of genitourinary malignancies, specifically bladder and prostate cancers. The global aging population contributes to a surge in these conditions, demanding a wide array of pharmacological treatments, from localized intravesical therapies to systemic chemotherapies. Global statistics underscore this need; the World Health Organization reported an estimated 614,298 new cases of bladder cancer worldwide in 2022, while prostate cancer accounted for 7.3% of all newly diagnosed cancer cases globally in 2024, as per the American Cancer Society. This growing disease burden ensures a sustained need for effective urological pharmaceuticals across all stages of disease progression.

Significant advancements in biologics and targeted drug delivery systems are transforming the competitive environment and propelling revenue growth. Pharmaceutical companies are increasingly directing their research towards antibody-drug conjugates (ADCs) and immune checkpoint inhibitors, moving beyond traditional chemotherapies to provide enhanced efficacy for difficult-to-treat cases. This shift is exemplified by the rapid market penetration of new therapies for urothelial carcinoma, with Astellas Pharma Inc. reporting global sales of its targeted therapy Padcev reaching ¥164.1 billion in fiscal year 2024, marking a 92% year-on-year increase. Such innovations enhance patient outcomes and also command higher prices, consequently boosting the overall value of the genitourinary drugs market.

Market Challenge

The expiration of patents on key blockbuster medications presents a substantial obstacle to the financial growth of the global genitourinary drugs market. Once market exclusivity concludes for established treatments for conditions like prostate cancer or benign prostatic hyperplasia, there is an immediate surge of more affordable generic and biosimilar competitors. This phenomenon quickly diminishes the market share of original drug manufacturers and drastically reduces the sector's total monetary value, as premium branded drug pricing is replaced by the lower costs of generics, thereby shrinking critical industry revenue streams.

This decrease in revenue fosters an unpredictable landscape, limiting the capital available for pharmaceutical companies to undertake the high-risk research and development necessary for bringing innovative urological compounds through regulatory processes. The financial shift from branded drug revenue to system savings is considerable; for instance, the Association for Accessible Medicines reported that biosimilar utilization led to $20.2 billion in savings in 2024. This significant figure demonstrates the deep financial repercussions of lost exclusivity, confirming that reduced per-unit revenue impedes the market's capacity for sustained economic expansion.

Market Trends

The adoption of radioligand therapies for metastatic prostate cancer marks a significant evolution in precision oncology, offering targeted radiation directly to prostate-specific membrane antigen positive cells. This approach provides a powerful new option for patients whose disease has progressed despite treatment with androgen receptor pathway inhibitors and taxane-based chemotherapy, thus moving beyond conventional systemic therapies. The commercial success of this class is underscored by the swift market acceptance of these novel radiopharmaceuticals, with Novartis reporting Pluvicto sales of $386 million in Q3 2024, a 50% year-over-year increase. This growth demonstrates the expanding clinical integration of radioligands as a standard treatment for advanced prostate cancers.

The growing use of PARP inhibitors for castration-resistant prostate cancer is reshaping therapeutic guidelines by leveraging synthetic lethality in tumors exhibiting homologous recombination repair gene mutations. This trend signifies a shift towards biomarker-guided treatment approaches, where patient selection is based on specific genetic characteristics like BRCA1 or BRCA2 mutations. Pharmaceutical firms are leveraging this by obtaining approvals for PARP inhibitors in conjunction with anti-androgens, aiming to slow disease progression in earlier metastatic contexts. AstraZeneca's Lynparza sales, which increased by 13% in the third quarter of 2024, confirm its continued market strength and the increasing role of PARP inhibition in urological oncology.

Key Market Players

  • Abbott laboratories Ltd.
  • Bristol-Myers Squibb Co.
  • Novartis AG
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Ionis Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • AstraZeneca Plc.

Report Scope

In this report, the Global Genitourinary Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genitourinary Drugs Market, By Indication

  • Prostate Cancer
  • Ovarian Cancer
  • Bladder Cancer
  • Cervical Cancer
  • Renal Cancer
  • Erectile Dysfunction
  • Urinary Tract Infections
  • Urinary Incontinence & Overactive Bladder
  • Sexually Transmitted Diseases
  • Interstitial Cystitis
  • Hematuria
  • Benign Prostatic Hyperplasia

Genitourinary Drugs Market, By Product

  • Hormonal Therapy
  • Gynecological
  • Urologicals
  • Anti-infectives
  • others

Genitourinary Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genitourinary Drugs Market.

Available Customizations:

Global Genitourinary Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genitourinary Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia)
    • 5.2.2. By Product (Hormonal Therapy, Gynecological, Urologicals, Anti-infectives, others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Genitourinary Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Product
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Genitourinary Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Product
    • 6.3.2. Canada Genitourinary Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Product
    • 6.3.3. Mexico Genitourinary Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Product

7. Europe Genitourinary Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Product
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Genitourinary Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Product
    • 7.3.2. France Genitourinary Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Product
    • 7.3.3. United Kingdom Genitourinary Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Product
    • 7.3.4. Italy Genitourinary Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Product
    • 7.3.5. Spain Genitourinary Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Product

8. Asia Pacific Genitourinary Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Product
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Genitourinary Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Product
    • 8.3.2. India Genitourinary Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Product
    • 8.3.3. Japan Genitourinary Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Product
    • 8.3.4. South Korea Genitourinary Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Product
    • 8.3.5. Australia Genitourinary Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Product

9. Middle East & Africa Genitourinary Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Product
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Genitourinary Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Product
    • 9.3.2. UAE Genitourinary Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Product
    • 9.3.3. South Africa Genitourinary Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Product

10. South America Genitourinary Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Product
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Genitourinary Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Product
    • 10.3.2. Colombia Genitourinary Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Product
    • 10.3.3. Argentina Genitourinary Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Product

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Genitourinary Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott laboratories Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb Co.
  • 15.3. Novartis AG
  • 15.4. Genentech, Inc.
  • 15.5. F. Hoffmann-La Roche Ltd.
  • 15.6. Ionis Pharmaceuticals, Inc.
  • 15.7. Eli Lilly and Company
  • 15.8. Merck & Co., Inc.
  • 15.9. Pfizer, Inc.
  • 15.10. AstraZeneca Plc.

16. Strategic Recommendations

17. About Us & Disclaimer